Jefferies (NYSE:JEF) analyst Michael Yee maintained a Buy rating on Cerevel Therapeutics Holdings on Tuesday, setting a price target of $22, which is approximately 55.48% above the present share price of $14.15.
Yee expects Cerevel Therapeutics Holdings to post earnings per share (EPS) of -$0.27 for the second quarter of 2021.
The current consensus among 1 TipRanks analysts is for a Moderate Buy rating of shares in Cerevel Therapeutics Holdings, with an average price target of $22.
The analysts price targets range from a high of $22 to a low of $22.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $0 and a net profit of -$41.9 million. The company's market cap is $1.8 billion.
According to TipRanks.com, Jefferies analyst Michael Yee is currently ranked with 3 stars on a 0-5 stars ranking scale, with an average return of 5.1% and a 47.95% success rate.
ARYA Sciences Acquisition Corp II is a blank check company.